Sernova Corp T.SVA

Alternate Symbol(s): SEOVF

Healthcare Medical Devices

Sernova Corp. is a Canada-based clinical-stage biotechnology company, which is developing therapeutic cell technologies for chronic diseases, including insulin-dependent diabetes, thyroid disease, and blood disorders that include hemophilia A. The Company is focused on developing a functional cure for insulin-dependent diabetes with its therapeutic cell technology, the Cell Pouch System, a novel implantable and scalable medical device with immune protected therapeutic cells. The Cell Pouch is a scalable, implantable medical device. The Cell Pouch is designed to create a vascularized organ-like environment for the transplantation and engraftment of therapeutic cells. Its regenerative medicine therapeutic approach is to provide cell therapies where the cells, transplanted within an organ-like vascularized implantable device, the Cell Pouch, generates proteins, hormones or factors released into the bloodstream for treatment of diseases requiring replacement of these molecules in the body.

TSX:SVA - Post by User

Sernova Corp

Bullboard Posts

Comment by elgin1on Jun 24, 2020 6:30pm

96 Views

Post# 31188150

RE:ViaCyte

BioTeck wrote: And now, a message from my employer: https://xconomy.com/san-diego/2020/05/26/viacyte-adds-27m-to-move-ahead-trio-of-stem-cell-diabetes-treatments/

Bioteck ... lol your employer lol

A few things why would they mention they hired Vertex exeecutive that was fired for personal reasons? Ian Smith ... must be desparate to hire soemone that has significant personal issues....

Money they raised was part of the original tranche. I think AgeX treatment for gene editing is far more superior than Viacycte/CrispX imo. Sva also has polymer coating immunosuppression which has had extensive preclinical data that should allow rapid movement for Fda clinical trials.

Viacycte also said they may go public ..That would be great ... maybe then you could go post on their blog Bioteck... may also increase the sp for Sva beacuse Viacyte is valued over $350 million US....no mention of any clinical updates by Viacycte.... show Fda their device does not fibrose ..... good luck with that.

Sva has several othet indications (Thyroid and Hemophilia) besides diabetes unlike Viacycte .

Starting to get interesting.

Elgin

Bullboard Posts

Eminent acquires promising Nevada gold project